An innovative and promising therapeutic strategy for the control of hypertension involves the inhibition of hepatic angiotensinogen (AGT) synthesis, thereby reducing the formation of angiotensin I and II and consequently attenuating the activation of angiotensin II type 1 and type 2 receptors [30]. This evidence concerns the gene AGT and Hypertension.